Centene stock is drifting lower today, down about 1% in afternoon trade around US$67. The move is mild, yet the latest Q3 2026 report is anything but dull. Management posted adjusted diluted earnings per share of US$0.58 and lifted full year guidance to more than US$5.20, putting the focus squarely on profit quality rather than the day's tick-by-tick price action.
Short term traders see a soft tape. Long term holders see a health insurer leaning into Medicare and Marketplace margin repair, and a P/E that still sits below peers while earnings forecasts extend several years into the future.
Like that Centene is leaning into earnings quality with raised EPS guidance but still uneasy about paying up for the next health insurer in your portfolio? Benchmark this setup against a curated screener of solid balance sheet and fundamentals stocks in our list of solid balance sheet and fundamentals stocks (24 results)
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs. Q3 2025):US$50,647 million vs. US$45,348 million (higher top line in the latest quarter)
-
Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025):loss of US$71 million vs. loss of US$6,631 million (materially smaller loss year on year)
-
Basic EPS (Q3 2026 vs. Q3 2025):loss of US$0.14 per share vs. loss of US$13.50 per share (meaningfully reduced per share loss)
-
Consolidated Health Benefits Ratio (HBR, Q3 2026 vs. Q3 2025):92.7% vs. prior year not specified (claims costs ran below internal expectations in the latest period)
Tired of skimming walls of earnings tables trying to piece together Centene's story by hand? Get the full visual breakdown of the business, with a clear view on valuation at a glance, in our company report for Centene.
Evaluating Centene's Mix And Margin Milestones
The bullish script says Centene's product mix and cost programs can turn execution into sturdier earnings power.
"Bullish analysts expect Centene to keep translating Medicaid, Marketplace, and Medicare execution into higher earnings power, supported by recent guidance raises and a stronger balance sheet."
Q3 results give that idea some hard markers. Medicare Advantage is now projected to hit breakeven in 2026, earlier than planned, while Part D pretax margins are guided to the mid to high 3% range. Marketplace pretax margin is tracking near 5%. Adjusted EPS guidance has been raised to more than US$5.20 and debt has fallen to about US$15.0b, with leverage around 41%.
One Narrative disagrees with today's price. → See where this Narrative says Centene should trade .
Centene Bear Case: Membership Pressure, Margins Holding
Bearish commentary focuses on whether Centene can convert AI and repricing initiatives into real profitability while Medicaid and Marketplace enrollment drifts lower.
"Although Centene is investing heavily in AI and advanced analytics to tighten forecasting and reduce fraud, waste and abuse, the expected 8% to 9% Medicaid membership decline from year end 2025 to year end 2026 signals that unit cost savings may be chasing a shrinking base, which could leave total Medicaid revenue and segment earnings below what current efficiency plans imply."
Q3 confirms the Medicaid membership drop and management still flags OB3 as a drag, so that part of the concern is materializing. At the same time, Medicaid trends remain in line with expectations. The Medicaid HBR around 93.5% and a steady 5% composite rate suggest margin repair is not slipping. Marketplace results show a similar pattern. Enrollment is pressured, but pretax margin is tracking near 5% and program integrity costs were absorbed. Earnings quality appears less like a one-off patch and more like measured progress, even as the revenue base is lighter than bullish investors might prefer.
Hunt For Quiet Mispricings
Centene just reported a detailed quarter that leaves investors debating its longer term direction. The real opportunity is hunting for stocks that could be undervalued before the market adjusts its view.
-
Company 1 - 23% below our estimate - uses a fast-growing surgical robotics platform and higher acuity procedures to deepen its role inside operating rooms.
-
Company 2 - 19% below our estimate - grows a network of franchised teahouses where improving overseas GMV reshapes store economics and its market mix.
-
Company 3 - 26% below our estimate - sells injectable treatments for weight loss and diabetes that are becoming the default option when payors approve coverage.
Three companies from the same screener. Open every one of the 29 undervalued companies on it →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CNC .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
